Summit Therapeutics ( (SMMT) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Summit Therapeutics shares are surging after the company formalized a broader clinical collaboration with AstraZeneca and Daiichi Sankyo to test its lead cancer drug, ivonescimab, alongside other oncology treatments in multiple tumor types. The rally is being fueled by a recent $2 billion equity investment from AstraZeneca at a premium price of $18.36 per share, which strengthens Summit’s cash position and underscores confidence ahead of an FDA decision expected on November 14, 2026.
Investors are encouraged by ivonescimab’s strong Phase III results across several cancer settings, which suggest the drug could have staying power in the market if regulators sign off. At the same time, Summit remains a high-risk story: the company is still pre-revenue, burning significant cash to fund large global trials, and faces critical regulatory hurdles that could delay or limit commercialization if survival benchmarks or statistical requirements are not met.
More about Summit Therapeutics
YTD Price Performance: -1.03%
Average Trading Volume: 5,671,242
Technical Sentiment Signal: Strong Buy
Current Market Cap: $13.78B
For further insights into SMMT stock on
TipRanks’ Stock Analysis page.
See more of today’s
top stock gainers and losers.